Gilead Sciences, Inc. (GILD)

Gilead Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	484	5,665	4,592	6,225	123	5,386
Depreciation & Amortization	2,743	2,693	2,103	2,050	1,480	1,404
Share-Based Compensation	788	766	637	635	643	636
Other Operating Activities	4,466	-1,118	1,740	2,474	5,922	1,718
Operating Cash Flow	8,481	8,006	9,072	11,384	8,168	9,144
Operating Cash Flow Growth	-5.51%	-11.75%	-20.31%	39.37%	-10.67%	8.86%
Capital Expenditures	-581	-585	-728	-579	-650	-825
Acquisitions	-4,644	-1,152	-1,797	-1,584	-25,920	-4,251
Change in Investments	1,571	-528	60	-987	11,948	-2,307
Other Investing Activities	8	-	-1	19	7	-434
Investing Cash Flow	-3,646	-2,265	-2,466	-3,131	-14,615	-7,817
Dividends Paid	-3,830	-3,809	-3,709	-3,605	-3,449	-3,222
Share Issuance / Repurchase	-719	-768	-1,087	-377	-1,327	-1,540
Debt Issued / Paid	-270	-270	-1,500	-4,750	5,684	-2,750
Other Financing Activities	-261	-278	-173	-145	-138	-122
Financing Cash Flow	-5,080	-5,125	-6,469	-8,877	770	-7,634
Exchange Rate Effect	26	57	-63	-35	43	-2
Net Cash Flow	-218	673	74	-659	-5,634	-6,309
Free Cash Flow	7,900	7,421	8,344	10,805	7,518	8,319
Free Cash Flow Growth	-5.80%	-11.06%	-22.78%	43.72%	-9.63%	11.28%
Free Cash Flow Margin	28.78%	27.37%	30.59%	39.57%	30.45%	37.06%
Free Cash Flow Per Share	6.33	5.95	6.65	8.60	5.98	6.55

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).